FDA Approves Lipfendra, the First Oral Pill Designed to Lower LDL Cholesterol
The FDA approved Lipfendra on July 16, 2026, making it the first oral PCSK9 inhibitor cleared for lowering LDL cholesterol in adults. The drug, developed by Merck, offers a pill-based alternative to injectable PCSK9 inhibitors already on the market. It is approved for adults with high cholesterol, including those with familial hypercholesterolemia.
The U.S. Food and Drug Administration approved Lipfendra on July 16, 2026, clearing the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults.
Lipfendra, developed by Merck under the generic name enlicitide, works by blocking the PCSK9 protein, which reduces the liver''s ability to clear LDL cholesterol from the blood. Existing PCSK9 inhibitors are administered by injection. Lipfendra is taken as a daily pill.
The drug is approved for adults with high LDL cholesterol, including those with familial hypercholesterolemia, a genetic condition that causes dangerously elevated cholesterol levels from birth. Clinical trials showed Lipfendra reduced LDL levels significantly compared to placebo.
Cardiologists said the approval is a meaningful step for patients who have difficulty with injectable medications or who prefer an oral option. High LDL cholesterol is a major risk factor for heart attack and stroke.
Statins remain the most widely prescribed cholesterol-lowering drugs. Lipfendra is expected to be used in patients who cannot tolerate statins or who need additional LDL reduction beyond what statins provide.
Merck has not yet announced the drug''s price. Insurance coverage and patient access will be key factors in how widely the medication is adopted. The FDA''s approval was based on data from multiple clinical trials involving thousands of patients.
